Merck, known as MSD outside of the United States and Canada, and Hanmi Pharmaceutical announced that the companies have entered into an exclusive licensing agreement for the development, manufacture and commercialization of efinopegdutide (formerly HM12525A), Hanmi’s investigational once-weekly glucagon-like peptide-1 (GLP-1)/glucagon receptor dual agonist, for the treatment of nonalcoholic steatohepatitis (NASH). Read more.
Pages
- Careers
- Certification of products subject to the requirements of the Consumer Product Safety Improvement Act of 2008 (CPSIA)
- Contact us
- Copyright
- Data science and artificial intelligence
- Forward-looking statement
- ical
- Merck | Home
- Products list
- Responsible Vulnerability Disclosure Program of Merck & Co., Inc., Rahway, NJ, USA
- Sitemap
- Stories
- Terms of use
- What we do
- Who we are
- History
- Sustainability
- Access to health
- Environmental sustainability
- Impact Venture Fund
- Merck Medical Outreach Program
- Philanthropy
- Advancing equity in cancer care
- Advancing patient-centered cancer care
- Advancing patient-centered cancer care in resource-limited communities
- Enhancing diabetes care through community outreach and support
- Expanding access to cancer care in Asia
- Global emergency response
- Improving access to high-quality diabetes care
- Improving access to HIV care in sub-Saharan Africa
- Improving health care access
- Merck Foundation
- Patient assistance and product donation programs
- Promoting equity in HIV/AIDS care
- Richard T. Clark Fellowship for Global Health
- Solutions for Healthy Communities
- Strengthening health systems’ resilience through immunization
- Strengthening our communities
- Strengthening our communities
- Sustainability resources
- Transparency disclosures
- Leadership
- Culture & values
- Diversity & inclusion
- Policies & positions
- Suppliers
- Research
- Areas of focus
- Business development and licensing (BD&L)
- CHLOR-TRIMETON
- Eyebiotech Limited (EyeBio)
- Immunology
- Meet our scientists
- Neuroscience
- Postdoctoral research fellows program
- Publications
- Scientific capabilities
- Vaccines
- COVID-19
- Infectious diseases
- Oncology
- Cardio-metabolic diseases
- Pipeline
- Discovery & development
- Clinical trials
- Diversity in clinical trials
- R&D locations
- Patients
- Investor relations
- Media
Archives
Categories
- No categories